@article{557657acfe354dfdb5ddee5ae7e1f06b,
title = "Long-acting antipsychotics: is what we know really so? – Authors' reply",
author = "Taishiro Kishimoto and Katsuhiko Hagi and Shunya Kurokawa and Kane, {John M.} and Correll, {Christoph U.}",
note = "Funding Information: TK reports personal fees from Banyu, Eli Lilly, Janssen, Kyowa Pharmaceutical Industry, Lundbeck, Novartis, Otsuka, Sumitomo Dainippon, and Takeda; and grants from Sumitomo Dainippon and Otsuka. KH is an employee of Sumitomo Dainippon Pharma. SK reports personal fees from Dainippon-Sumitomo Pharma, Meiji-Seika Pharma, and Mochida Pharmaceutical. JMK reports personal fees from Alkermes, Acadia, Dainippon Sumitmo, Intracellular Therapies, Merck, Neurocrine, Reviva, Roche, Saladex, Sunovion, Takeda, Teva, and LB Pharma; and grants and personal fees from H Lundbeck, Janssen, and Otsuka. JMK is also a shareholder of LB Pharma and The Vanguard Research Group. CUC reports personal fees from Acadia, Alkermes, Allergan, Angelini, Axsome, Bristol-Myers Squibb, Gedeon Richter, IntraCellular Therapies, Janssen (Johnson & Johnson), Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva; and royalties from UpToDate. CUC is also a stock option holder of LB Pharma. TK and KH contributed equally to this Correspondence.",
year = "2021",
month = aug,
doi = "10.1016/S2215-0366(21)00249-2",
language = "English",
volume = "8",
pages = "651--652",
journal = "The Lancet Psychiatry",
issn = "2215-0366",
publisher = "Elsevier Limited",
number = "8",
}
